Alcoholism, or alcohol use disorder (AUD), presents as a chronic and incapacitating condition marked by an inability to restrain or moderate alcohol intake despite its adverse effects on physical health, mental stability, relationships, and overall well-being. Those afflicted often experience an intense desire for alcohol, sometimes prioritizing its consumption over other obligations. The causes of alcoholism are diverse, encompassing genetic predispositions, environmental influences, psychological factors, and societal pressures. Genetics play a significant role, as certain genetic variations may heighten susceptibility to AUD. Environmental stressors, trauma, peer influence, and exposure to heavy drinking also contribute to its development. Alcoholism manifests various health complications, including liver disease, cardiovascular issues, neurological impairments, gastrointestinal disorders, and an elevated risk of specific cancers. Moreover, individuals with alcoholism are more prone to mental health ailments such as depression, anxiety, and psychosis. Treatment typically involves a blend of medical assistance, therapy, support groups, and lifestyle adjustments. Detoxification may be necessary to manage withdrawal symptoms, followed by ongoing therapy and support to address underlying issues fueling alcohol abuse. Support from loved ones, peers, and healthcare providers is vital in the recovery journey, as overcoming alcoholism alone can be arduous. Early intervention and comprehensive treatment approaches are imperative for enhancing outcomes and mitigating the profound societal impact of alcoholism.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States